focus -WSS

focus

author：focus 2025-09-27 09:38:04 - browse：331

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Dewpoint Therapeutics lays off staff after losing partnerships

explore

hotspot

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Lack of darker skin in textbooks, journals harms patients of color

Copay coupons to count toward deductibles, after Biden court move

Eli Lilly, Pfizer, and others want in on the online prescription market

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Research misconduct: Proposed new rules face resistance

leisure time

focus

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Lack of darker skin in textbooks, journals harms patients of color

Drug repurposing or repositioning? The language matters

More hospitals are billing patients as online messages surge

Guidelines to prevent youth baseball injuries need more muscle

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

After affirmative action ruling, medical educators look to 'holistic review'

Robert Kennedy Jr.'s presidential campaign attracts GOP

Apple is now the first public company to be valued at $3 trillion

Parkinson’s finding may lead to tests and, someday, treatments

entertainment

FDA clears AI tool for detecting skin cancer

Copay coupons to count toward deductibles, after Biden court move

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

NIH director takes cautious approach to Biden drug pricing priority

More hospitals are billing patients as online messages surge

Why you get paid to donate plasma but not blood

knowledge

explore

hotspot

focus